3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
2
Other hematologic neoplasm
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Conditions
Ovarian Neoplasms
20
Uterine Cervical Neoplasms
19
Endometrial Neoplasms
9
Stomach Neoplasms
8
Melanoma
8
Carcinoma, Renal Cell
8
Squamous Cell Carcinoma of Head and Neck
7
Colorectal Neoplasms
7
Carcinoma, Non-Small-Cell Lung
7
Fallopian Tube Neoplasms
6
Carcinoma, Hepatocellular
6
Breast Neoplasms
6
Pancreatic Neoplasms
5
Carcinoma, Transitional Cell
5
Triple Negative Breast Neoplasms
4
Neoplasms
4
Neoplasm Metastasis
4
Head and Neck Neoplasms
4
Esophageal Neoplasms
4
Carcinoma, Merkel Cell
4
Small Cell Lung Carcinoma
3
Prostatic Neoplasms
3
Sarcoma
2
Recurrence
2
Microsatellite Instability
2
Lymphoma
2
Kidney Neoplasms
2
Carcinoma, Squamous Cell
2
Carcinoma
2
Vulvar Neoplasms
1
Interventions
trametinib
1
enzalutamide
1
dabrafenib
1
atezolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoproliferative Disorders
×
atezolizumab
×
Gynecologic
×
Clear all
NCT05770102
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled